Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Abeona Therapeutics director Mark Alvino reported a bona fide gift of 500 shares of Common Stock. The gift was recorded at a price of $0.00 per share, reflecting a non-market, no‑consideration transfer. Following this disposition, he directly holds 77,065 shares of Abeona Therapeutics common stock.
Abeona Therapeutics director Mark Alvino reported an open-market sale of company stock. He sold 6,500 shares of common stock on May 22, 2026 at a weighted average price of $5.4558 per share, through multiple trades priced between $5.44 and $5.47.
After this transaction, Alvino directly holds 77,565 shares of Abeona Therapeutics common stock. The filing notes that full details of the individual trade prices within the reported range are available upon request.
Abeona Therapeutics director Eric Crombez reported an open-market sale of 26,143 shares of common stock on May 15, 2026 at a weighted average price of $5.5325 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on February 4, 2026, indicating the transactions were pre-arranged. Following this sale, Crombez directly holds 37,313 shares of Abeona Therapeutics common stock.
ABEONA THERAPEUTICS INC. Schedule 13G/A amendment reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 5,775,350 shares of common stock as of March 31, 2026. The filing states these holdings represent 9.99% of the outstanding shares for each Reporting Person. The disclosure notes 762,298 shares of the total may be acquired within sixty days through the exercise of convertible securities. Shared voting and dispositive power over the 5,775,350 shares is recorded for Nantahala, Harkey and Mack.
ABEONA THERAPEUTICS INC. reports amended beneficial ownership by Nantahala Capital Partners. As of March 31, 2026, Nantahala may be deemed the beneficial owner of 3,333,757 shares, representing 5.82% of the class based on 57,049,023 shares outstanding as of December 31, 2025. The reported total includes 179,832 shares that may be acquired within sixty days upon exercise of securities. The filing shows shared voting and dispositive power over the full position.
ABEO filed a Form 144 reporting a proposed sale of Common Stock through Stifel Nicolaus on Nasdaq, dated 05/15/2026. The filing lists Restricted Stock Awards issued 08/13/2025 (6,326 shares) and 01/31/2026 (19,817 shares) that appear related to equity compensation.
Abeona Therapeutics reported its first meaningful commercial quarter for ZEVASKYN, generating $8.7 million in product revenue for the three months ended March 31, 2026. This compares to no revenue in the same period of 2025.
The company posted a net loss of $17.1 million, versus a $12.0 million loss a year earlier, as selling, general and administrative expenses rose to $19.5 million and research and development held roughly flat at $9.6 million. Loss from operations was $23.0 million.
Cash and cash equivalents were $61.4 million and short-term investments were $106.9 million, supporting total assets of $198.5 million and stockholders’ equity of $144.9 million. Management concluded existing capital resources are sufficient to fund operations for at least 12 months.
During the quarter Abeona signed a new license and joint development agreement with Reverence Enterprises for PSMA SIR-T T-cell therapy for prostate cancer, paying a $7.0 million upfront fee that was expensed as research and development. Warrant liabilities declined to $13.5 million as their fair value decreased.
Abeona Therapeutics reported first-quarter 2026 results highlighted by early ZEVASKYN commercialization and a new T‑cell therapy license. Net product revenue reached $8.7 million, a $6.3 million increase over the fourth quarter of 2025, driven by three ZEVASKYN patient treatments in the quarter.
Cost of sales was $2.7 million, while R&D totaled $9.6 million, including a $7.0 million upfront payment to in‑license PSMA‑SIR‑T, now ABO‑701. Selling, general and administrative expenses rose to $19.5 million as the company scaled commercial operations.
Abeona reported a net loss of $17.1 million, or $0.30 per share, compared with a $12.0 million loss a year earlier. Cash, cash equivalents and short‑term investments were $168.3 million as of March 31, 2026. The ZEVASKYN qualified treatment center network expanded to six sites, coverage policies now reach 95% of commercially insured U.S. lives, and the company plans to file an IND and begin first‑in‑human studies for ABO‑701 in the second half of 2027 while deprioritizing in‑house ophthalmology programs.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 5,548 shares of common stock at a weighted average price of $5.9613 per share. According to the filing, this sale was made specifically to cover tax obligations from the vesting of restricted stock awards, making it a mechanistic transaction rather than a discretionary portfolio change. Following the sale, Vasanthavada directly holds 313,071 shares of Abeona common stock, so the transaction represents a small portion of his overall reported holdings.